Earnings · US stocks

Nektar Therapeutics (NKTR) earnings

Nektar Therapeutics published its quarterly report on 2026-11-12. The stock moved -3.60% in the 3 trading days after the report.

Report
quarterly report
Published
2026-11-12
Result
Bad / loss
Open earnings in Wave Radar

Stock move after the report

Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.

AfterReturnvs index
1 day+0.05%—
3 days-3.60%—

Report history

Over the last 8 reports, EPS beat the consensus estimate in 6 of them. The stock rose in the 3 trading days after 5 of 8 reports (average +4.46%).

PublishedEPSEPS surprise3 days after30 days after30d vs index
2026-11-12-1.63+21.23%-3.60%——
2026-08-13-1.21+40.54%-3.00%-24.84%-24.00%
2026-05-07-1.78-20.47%-5.93%-21.19%-22.95%
2026-03-12-1.29+63.10%+6.68%+30.30%+23.11%
2025-11-06-1.87+33.03%+7.51%-15.02%-16.56%
2025-08-07-2.78+10.89%+8.51%+153.52%+148.54%
2025-05-08-3.61-27.71%+14.52%-93.16%-99.37%
2025-03-12-2.25+23.08%+10.98%-9.76%-7.58%

The last 8 reported quarters. Moves count trading days from the first tradeable session after the report; "30d vs index" is the excess return over the market index.

Stock valuations: NKTR

How to read this

Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.

Figures are generated automatically from Wave Radar's published market data and refresh after each market close.